

Edgar Filing: VIREXX MEDICAL CORP - Form 6-K

VIREXX MEDICAL CORP
Form 6-K
December 12, 2005

FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month ended

Commission File
Number
1-32608

December 2005

VIREXX MEDICAL CORP.
(Translation of registrant's name
into English)

8223 Roper Road NW, Edmonton,
Alberta, Canada T6E 6S4
(Address of principal executive
offices)

Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-
K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-
K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.

Yes No ..X..

If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b): 82- _____

EXHIBIT LIST

Exhibit	Description
99.1 News Release	(ViRexx Files Clinical Trial Application For Hepatitis B Therapeutic Vaccine)

Edgar Filing: VIREXX MEDICAL CORP - Form 6-K

99.2 News Release (ViRexx Announces Founder Dr. Antoine
Noujaim Honoured With Centennial Medal)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

VIREXX MEDICAL CORP.

Date: December 8, 2005

By: /s/ Marc Canton

Marc Canton, President